[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB0404124D0 - Antagonists of GIP - Google Patents

Antagonists of GIP

Info

Publication number
GB0404124D0
GB0404124D0 GBGB0404124.0A GB0404124A GB0404124D0 GB 0404124 D0 GB0404124 D0 GB 0404124D0 GB 0404124 A GB0404124 A GB 0404124A GB 0404124 D0 GB0404124 D0 GB 0404124D0
Authority
GB
United Kingdom
Prior art keywords
gip
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0404124.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ulster University
Original Assignee
Ulster University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulster University filed Critical Ulster University
Priority to GBGB0404124.0A priority Critical patent/GB0404124D0/en
Publication of GB0404124D0 publication Critical patent/GB0404124D0/en
Priority to CA2557151A priority patent/CA2557151C/en
Priority to JP2007500292A priority patent/JP2008500280A/en
Priority to AU2005217198A priority patent/AU2005217198A1/en
Priority to EP05717793A priority patent/EP1730188A2/en
Priority to PCT/GB2005/000710 priority patent/WO2005082928A2/en
Priority to US11/090,787 priority patent/US20050272652A1/en
Priority to US11/713,892 priority patent/US7875587B2/en
Priority to US11/825,293 priority patent/US20080009603A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB0404124.0A 1999-03-29 2004-02-25 Antagonists of GIP Ceased GB0404124D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0404124.0A GB0404124D0 (en) 2004-02-25 2004-02-25 Antagonists of GIP
CA2557151A CA2557151C (en) 2004-02-25 2005-02-25 Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity
JP2007500292A JP2008500280A (en) 2004-02-25 2005-02-25 GIP peptide analogs for the treatment of diabetes, insulin resistance, and obesity
AU2005217198A AU2005217198A1 (en) 2004-02-25 2005-02-25 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP05717793A EP1730188A2 (en) 2004-02-25 2005-02-25 Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity
PCT/GB2005/000710 WO2005082928A2 (en) 2004-02-25 2005-02-25 Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity
US11/090,787 US20050272652A1 (en) 1999-03-29 2005-03-25 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US11/713,892 US7875587B2 (en) 1999-03-29 2007-03-05 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US11/825,293 US20080009603A1 (en) 1999-03-29 2007-07-03 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0404124.0A GB0404124D0 (en) 2004-02-25 2004-02-25 Antagonists of GIP

Publications (1)

Publication Number Publication Date
GB0404124D0 true GB0404124D0 (en) 2004-03-31

Family

ID=32050802

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0404124.0A Ceased GB0404124D0 (en) 1999-03-29 2004-02-25 Antagonists of GIP

Country Status (6)

Country Link
EP (1) EP1730188A2 (en)
JP (1) JP2008500280A (en)
AU (1) AU2005217198A1 (en)
CA (1) CA2557151C (en)
GB (1) GB0404124D0 (en)
WO (1) WO2005082928A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113827706A (en) * 2021-09-27 2021-12-24 南通大学 Application of GIP and peptide derived from GIP in preparation of skin wound treatment drug

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580919A1 (en) 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
CA2623412A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CA2660835A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EP2487184A1 (en) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
GB0717388D0 (en) * 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP5669582B2 (en) 2007-10-30 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon antagonist
US8710002B2 (en) * 2007-11-23 2014-04-29 Michael Rothkopf Methods of enhancing diabetes resolution
JP5753779B2 (en) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analogs with improved solubility and stability in buffers at physiological pH
AR072160A1 (en) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp GLUCAGON / GLP-1 RECEIVER CO-AGONISTS
EP2952202B1 (en) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
GB0814068D0 (en) * 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
KR20110043688A (en) * 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 Glucose-dependent insulinotropic polypeptide analogues
WO2010016935A2 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
KR101417873B1 (en) 2008-08-07 2014-07-09 입센 파마 에스.에이.에스 Analogues of glucose-dependent insulinotropic polypeptide
KR101593158B1 (en) 2008-08-07 2016-02-12 입센 파마 에스.에이.에스. Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
JP5576694B2 (en) * 2009-04-10 2014-08-20 花王株式会社 GIP elevation inhibitor
CN102459325B (en) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 Gip receptor-active glucagon compounds
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
JP2013518115A (en) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
JP6050746B2 (en) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Glucagon superfamily of peptides exhibiting G protein-coupled receptor activity
MX2012013001A (en) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting nuclear hormone receptor activity.
US9023986B2 (en) * 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
RU2014101697A (en) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon receptor coagonists / GLP-1
EP2780031B1 (en) 2011-11-17 2018-03-07 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
RU2015101697A (en) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн GLUCAGON ANALOGUES WITH GIP RECEPTOR ACTIVITY
CA2965732A1 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
JOP20180028A1 (en) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co Peptide compound
BR112019025195A8 (en) * 2017-05-31 2020-07-07 Univ Copenhagen long-acting gip peptide analogues
TWI770085B (en) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 Peptide compound
TWI707865B (en) 2018-05-04 2020-10-21 丹麥商諾佛 儂迪克股份有限公司 Gip derivatives and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367856C (en) * 1999-03-29 2013-10-15 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113827706A (en) * 2021-09-27 2021-12-24 南通大学 Application of GIP and peptide derived from GIP in preparation of skin wound treatment drug
CN113827706B (en) * 2021-09-27 2023-12-26 南通大学 Application of GIP and its derivative peptide in preparing skin wound treating medicine

Also Published As

Publication number Publication date
WO2005082928A3 (en) 2005-12-01
CA2557151A1 (en) 2005-09-09
JP2008500280A (en) 2008-01-10
EP1730188A2 (en) 2006-12-13
CA2557151C (en) 2015-02-17
AU2005217198A1 (en) 2005-09-09
WO2005082928A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
GB0404124D0 (en) Antagonists of GIP
PL1963369T3 (en) Il-21 antagonists
ZA200803811B (en) Neuropolin antagonists
IL181848A0 (en) Substituted bicyclic imidazo-3-yl-amine compounds
IL178029A0 (en) Use of sulfonylureas
IL182828A0 (en) Constrained compounds as cgrp-receptor antagonists
IL180587A0 (en) Heterocyclic compounds
HK1112457A1 (en) Substituted piperazines as cb1 antagonists
EP1940412A4 (en) Novel opioid antagonists
IL183665A0 (en) Heterocyclic compounds as ccr2b antagonists
EP1717239A4 (en) Substituted sym-triindole
TWI348467B (en) Nk1 antagonists
IL180888A0 (en) Substituted n-acyl-2-aminothiazoles
EP1732560A4 (en) Substituted cinnolin-4-ylamines
PT1763520E (en) Use of trisubstituted benzopyranones
EP1806147A4 (en) Use of immunesuppressant receptor
EP1799653A4 (en) Novel heterocycles
ZA200700723B (en) Substituted N-acyl-2-aminothiazoles
ZA200705159B (en) Heterocyclic compounds as CCR2B antagonists
ZA200703525B (en) Constrained compounds as CGRP-receptor antagonists
GB0426567D0 (en) Transformer
GB0418238D0 (en) Up yours- Barb-B-Q
GB0425729D0 (en) Heterocyclic compounds
GB0410433D0 (en) Anti-slug collar
GB0404518D0 (en) Protection of sanitaryware

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)